Imakita Takuma, Fujita Kohei, Ito Takanori, Saito Zentaro, Oi Issei, Kanai Osamu, Tachibana Hiromasa, Sawai Satoru, Mio Tadashi
Division of Respiratory Medicine, Center for Respiratory Diseases, National Hospital Organization Kyoto Medical Center, 1-1, Fukakusa-Mukaihata, Fushimi, Kyoto, 612-8555, Japan.
Division of Thoracic Surgery, Center for Respiratory Diseases, National Hospital Organization, Kyoto Medical Center, 1-1, Fukakusa-Mukaihata, Fushimi, Kyoto, 612-8555, Japan.
Discov Oncol. 2023 Aug 31;14(1):163. doi: 10.1007/s12672-023-00781-5.
The role of re-immunotherapy in advanced non-small cell lung cancer (NSCLC) remains unclear. No studies have evaluated the re-immunotherapy regimen including anti-cytotoxic T-lymphocyte antigen-4 antibody for lung cancer treatment. This study aimed to investigate the efficacy and safety of re-immunotherapy with nivolumab plus ipilimumab in patients with advanced NSCLC previously treated with anti-programmed death-1 (PD-1) and/or anti-programmed death ligand-1 (PD-L1) antibodies.
We retrospectively reviewed patients with advanced or recurrent NSCLC who received immunotherapy with nivolumab plus ipilimumab (without concomitant cytotoxic chemotherapy) between November 2020 and November 2022 at the National Hospital Organization Kyoto Medical Center, Kyoto, Japan. Data were extracted from patients who had previously received immunotherapies with anti-PD-1 and/or anti-PD-L1 antibodies. Treatment responses and adverse events were evaluated.
Of the 67 patients who received immunotherapy with nivolumab plus ipilimumab, 23 were included in final analysis. The objective response rate was 17%, and the disease control rate was 48% for nivolumab plus ipilimumab therapy. The highest grade of immune-related adverse events was grade 3, occurring in 11% of cases.
Re-immunotherapy with nivolumab plus ipilimumab after anti-PD-1 and/or anti-PD-L1 immunotherapy may be feasible and provide clinical benefit in selected patients. Further prospective studies are warranted to identify the patient population that may benefit from re-immunotherapy.
再免疫疗法在晚期非小细胞肺癌（NSCLC）中的作用仍不明确。尚无研究评估包括抗细胞毒性T淋巴细胞抗原4抗体在内的再免疫疗法方案用于肺癌治疗的效果。本研究旨在探讨纳武利尤单抗联合伊匹木单抗进行再免疫疗法对先前接受过抗程序性死亡蛋白1（PD-1）和/或抗程序性死亡配体1（PD-L1）抗体治疗的晚期NSCLC患者的疗效和安全性。
我们回顾性分析了2020年11月至2022年11月期间在日本京都国立医院机构京都医疗中心接受纳武利尤单抗联合伊匹木单抗免疫疗法（不联合细胞毒性化疗）的晚期或复发性NSCLC患者。数据提取自先前接受过抗PD-1和/或抗PD-L1抗体免疫疗法的患者。评估治疗反应和不良事件。
在67例接受纳武利尤单抗联合伊匹木单抗免疫疗法的患者中，23例纳入最终分析。纳武利尤单抗联合伊匹木单抗治疗的客观缓解率为17%，疾病控制率为48%。免疫相关不良事件的最高级别为3级，发生率为11%。
在抗PD-1和/或抗PD-L1免疫疗法后采用纳武利尤单抗联合伊匹木单抗进行再免疫疗法可能是可行的，并可为部分患者带来临床益处。有必要开展进一步的前瞻性研究以确定可能从再免疫疗法中获益的患者群体。
